103 related articles for article (PubMed ID: 26717998)
1. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
[TBL] [Abstract][Full Text] [Related]
2. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK
BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184
[TBL] [Abstract][Full Text] [Related]
3. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
Kinslow CJ; Mercurio A; Kumar P; Rae AI; Siegelin MD; Grinband J; Taparra K; Upadhyayula PS; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Kachnic LA; Yu JB; Cheng SK; Wang TJC
JAMA Oncol; 2023 Jul; 9(7):919-927. PubMed ID: 37200021
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
5. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.
Brandes AA; Franceschi E; Tosoni A; Bartolini S; Bacci A; Agati R; Ghimenton C; Turazzi S; Talacchi A; Skrap M; Marucci G; Volpin L; Morandi L; Pizzolitto S; Gardiman M; Andreoli A; Calbucci F; Ermani M
Neuro Oncol; 2010 Mar; 12(3):283-8. PubMed ID: 20167816
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation in 1p19q-intact gliomas.
Kinslow CJ; Siegelin MD; Iwamoto FM; Gallitto M; Neugut AI; Yu JB; Cheng SK; Wang TJC
J Neurooncol; 2024 Jan; 166(1):73-78. PubMed ID: 38114801
[TBL] [Abstract][Full Text] [Related]
7. Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma.
Zhang Y; Zhu J
Oncol Rep; 2019 Feb; 41(2):908-916. PubMed ID: 30535433
[TBL] [Abstract][Full Text] [Related]
8. Total DNA methylation profile in assessing the MGMT gene promoter status in malignant gliomas.
Petrova EI; Galstyan SA; Telysheva EN; Ryzhova MV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):52-58. PubMed ID: 38054227
[TBL] [Abstract][Full Text] [Related]
9. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
Zapanta Rinonos S; Li T; Pianka ST; Prins TJ; Eldred BSC; Kevan BM; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
J Neurooncol; 2024 Jan; 166(1):129-142. PubMed ID: 38224404
[TBL] [Abstract][Full Text] [Related]
10.
Kong Z; Lin Y; Jiang C; Li L; Liu Z; Wang Y; Dai C; Liu D; Qin X; Wang Y; Liu Z; Cheng X; Tian J; Ma W
Cancer Imaging; 2019 Aug; 19(1):58. PubMed ID: 31426864
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM].
Gibson D; Vo AH; Lambing H; Bhattacharya P; Tahir P; Chehab FF; Butowski N
BMC Neurol; 2024 Mar; 24(1):103. PubMed ID: 38521933
[TBL] [Abstract][Full Text] [Related]
12. Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay.
Buyuktepe M; Kaplan I; Bayatli E; Dogan H; Ugur HC
J Neurooncol; 2023 Aug; 164(1):171-177. PubMed ID: 37474746
[TBL] [Abstract][Full Text] [Related]
13. MRI-Based Deep-Learning Method for Determining Glioma
Yogananda CGB; Shah BR; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA
AJNR Am J Neuroradiol; 2021 May; 42(5):845-852. PubMed ID: 33664111
[TBL] [Abstract][Full Text] [Related]
14. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow CJ; Rae AI; Taparra K; Kumar P; Siegelin MD; Grinband J; Gill BJA; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Horowitz DP; Kachnic LA; Neugut AI; Yu JB; Cheng SK; Wang TJC
Clin Cancer Res; 2023 Nov; 29(21):4399-4407. PubMed ID: 37611077
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.
Oliver JA; Ortiz R; Melguizo C; Alvarez PJ; Gómez-Millán J; Prados J
BMC Cancer; 2014 Jul; 14():511. PubMed ID: 25015560
[TBL] [Abstract][Full Text] [Related]
16. Exploring MGMT methylation-driven structural connectivity changes in insular gliomas: a tractography and graph theoretical analysis.
Yang ZC; Yin CD; Yeh FC; Xue BW; Song XY; Li G; Sun SJ; Deng ZH; Hou ZG; Xie J
J Neurooncol; 2024 Jan; 166(1):155-165. PubMed ID: 38150062
[TBL] [Abstract][Full Text] [Related]
17. Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results.
McCord M; Jamshidi P; Thirunavu V; Santana-Santos L; Vormittag-Nocito E; Dittman D; Parker S; Baczkowski J; Jennings L; Walshon J; McCortney K; Galbraith K; Zhang H; Lukas RV; Stupp R; Dixit K; Kumthekar P; Heimberger AB; Snuderl M; Horbinski C
Acta Neuropathol Commun; 2023 Nov; 11(1):175. PubMed ID: 37919784
[TBL] [Abstract][Full Text] [Related]
18. MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas.
Zhao B; Qi H; Ma W
JAMA Oncol; 2023 Dec; 9(12):1734-1735. PubMed ID: 37856142
[No Abstract] [Full Text] [Related]
19. MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas-Reply.
Kinslow CJ; Cheng SK; Wang TJC
JAMA Oncol; 2023 Dec; 9(12):1735-1736. PubMed ID: 37856114
[No Abstract] [Full Text] [Related]
20. Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma.
Fleming JL; Pugh SL; Fisher BJ; Lesser GJ; Macdonald DR; Bell EH; McElroy JP; Becker AP; Timmers CD; Aldape KD; Rogers CL; Doyle TJ; Werner-Wasik M; Bahary JP; Yu HM; D'Souza DP; Laack NN; Sneed PK; Kwok Y; Won M; Mehta MP; Chakravarti A
JCO Precis Oncol; 2021; 5():. PubMed ID: 34589661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
